Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06854003 · ClinicalTrials.gov registry record · Phase 2

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

A Phase 2 study of Lymphoma and Mantle Cell Lymphoma, sponsored by Christine Ryan.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
7
Study locations

NCT06854003 is a Phase 2 study of Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by Christine Ryan. The registered enrollment target is 60 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06854003, a Phase 2 study of Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by Christine Ryan.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
7
Study locations

Study Summary

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL). The names of the study drugs involved in this study are: * bendamustine (a type of alkylating agent) * rituximab (a type of monoclonal antibody) * cytarabine (a type of antineoplastic) * zanubrutinib (a type of kinase inhibitor) * sonrotoclax (a type of BCL2 inhibitor)

Conditions Studied

Lymphoma Mantle Cell Lymphoma

Interventions

  • DRUG Zanubrutinib
  • DRUG Sonrotoclax
  • DRUG Rituximab
  • DRUG Cytarabine
  • DRUG Bendamustine

Study Locations (7)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Arizona

  • Mayo Clinic Arizona - Phoenix

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University - St Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-04-22
Est. Completion 2039-11-01
Phase Phase 2

Sponsor

Christine Ryan

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06854003

The ClinicalTrials.gov registry entry for NCT06854003 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The listed sponsor is Christine Ryan, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Zanubrutinib is the first listed.

NCT06854003 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT06854003 about?

NCT06854003 is a clinical study titled "BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma". This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL). T...

What is the current status of trial NCT06854003?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-04-22. Estimated completion is 2039-11-01.

What conditions does trial NCT06854003 study?

This clinical trial studies the following conditions: Lymphoma, Mantle Cell Lymphoma.

What interventions are being tested in trial NCT06854003?

The interventions under investigation include: Zanubrutinib (DRUG), Sonrotoclax (DRUG), Rituximab (DRUG), Cytarabine (DRUG), Bendamustine (DRUG).

Who is sponsoring clinical trial NCT06854003?

This trial is sponsored by Christine Ryan, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06854003 being conducted?

This trial has 7 study locations across Arizona, Massachusetts, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Mantle Cell Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.